Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinematic-calcium loops unravel impaired excitation-contraction coupling in MELAS-affected cardioids.

The Journal of physiology·2026
Same author

A deep learning framework for efficient pathology image analysis.

Nature communications·2026
Same author

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Journal of the National Cancer Institute·2026
Same author

SUBITO: validating biology, not intensity.

The Lancet. Oncology·2026
Same author

Cardiovascular and Renal Risk Stratification in Patients Referred to an Onconephrology Clinic and Undergoing Different Oncology Therapies: A Real-World Study.

Biomedicines·2026
Same author

Ill Fate of Rectal Mucinous Adenocarcinoma: A Defect in Immunosurveillance or a Mucin Coating Effect?-The IMMUNOREACT 20 Study.

Cancers·2026
Same journal

Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents.

Nature medicine·2026
Same journal

Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba.

Nature medicine·2026
Same journal

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Nature medicine·2026
Same journal

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same journal

Data rights are the missing pillar for modernizing consent in medicine.

Nature medicine·2026
Same journal

Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Nature medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.

Paolo Marchetti1, Giuseppe Curigliano2,3, Mauro Biffoni4

  • 1Department of Oncology, IDI-IRCCS, Rome, Italy.

Nature Medicine
|September 30, 2025
PubMed
Summary
This summary is machine-generated.

Tailored treatment (TT) significantly improved overall response rates and progression-free survival in advanced solid tumors compared to standard of care. This precision oncology approach shows promise for patients with actionable genomic alterations.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Related Experiment Videos

Last Updated: Jun 3, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • Limited randomized evidence exists for precision oncology's superiority over standard therapies.
  • Tumor-agnostic biomarkers show potential for guiding effective cancer treatments.

Purpose of the Study:

  • To compare tailored treatment (TT) versus standard of care (SoC) in advanced solid tumors.
  • To evaluate the efficacy and safety of precision oncology guided by comprehensive genomic profiling.

Main Methods:

  • Multicenter, randomized, open-label phase 2 ROME trial.
  • Comprehensive genomic profiling of tissue and blood to identify actionable alterations.
  • Molecular tumor board (MTB) recommendations guided treatment allocation.

Main Results:

  • Tailored treatment (TT) resulted in a significantly higher overall response rate (17.5% vs. 10%, P = 0.0294).
  • Median progression-free survival (PFS) improved with TT (3.5 vs. 2.8 months, P = 0.0002).
  • Superior 12-month PFS rates were observed in the TT arm (22.0% vs. 8.3%).

Conclusions:

  • Tailored treatment guided by genomic profiling and MTB recommendations significantly improves outcomes in advanced solid tumors.
  • These findings provide evidence supporting a tumor-agnostic precision oncology strategy.
  • TT demonstrates potential for patients with diverse actionable genomic alterations.